Have a look on slide 6 of the recent announcement
https://www.starpharma.com/assets/uploads/2020-06/200618%20SPL%20Investor%20Presentation%20-%20OTC%2018%20June%202020%20FINAL.pdf
They have retained fast track status for development and things still look hopeful IMO.
Targeted population groups are
• front-line healthcare workers
• other staff in high-risk environments e.g. aged care,
armed forces, police etc
• on public transport and airlines
• family members and carers of COVID-19 outpatients
Ann: DEP lutetium effective in human prostate cancer model, page-33
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
